AI Article Synopsis

  • The study examines how specific gene variations in CD36 relate to the effectiveness of photodynamic therapy (PDT) in treating polypoidal choroidal vasculopathy (PCV).
  • Out of 137 PCV patients treated with PDT, those who improved visually after 6 months (responders) showed different genetic markers compared to those who did not (non-responders), particularly with the SNP rs3173798.
  • The findings suggest that carrying a specific variant (C allele) in rs3173798 may lead to poorer visual outcomes after PDT, indicating a potential genetic influence on treatment response in PCV patients.

Article Abstract

Purpose: To clarify the association between cluster of differentiation 36 (CD36) gene polymorphisms and the response to photodynamic therapy (PDT) in polypoidal choroidal vasculopathy (PCV).

Methods: One hundred and thirty-seven patients with PCV were enrolled. The patients were treated with PDT and followed up for more than 6 months. Retreatments were performed every 3 months as needed based on findings from angiography. Patients who showed an improvement in their best-corrected visual acuity at 6 months post-PDT were classified as PDT responders, and the others were defined as non-responders. For the 73 responders and 64 non-responders, 19 single nucleotide polymorphisms (SNPs) across the CD36 region were genotyped using the TaqMan assay. We analyzed the association between these variants and the visual outcomes of PDT.

Results: The allelic frequencies of the SNPs rs3211851, rs3173798, and rs3211908 showed nominally significant differences between the PDT responders and non-responders. Genotype association analysis revealed a significant association of SNP rs3173798 with the visual outcome of PDT in a dominant model. The presence of the C allele in rs3173798 was significantly associated with a poor response to PDT after multivariate logistic regression analysis with clinical pre-PDT parameters. The mean best-corrected visual acuity in the group with the TT genotype of rs3173798 was significantly improved over 12 months of follow-up after the initial PDT.

Conclusions: The coding variants in CD36 are possibly associated with the visual outcome of PDT in patients with PCV.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513185PMC

Publication Analysis

Top Keywords

visual outcome
12
cd36 gene
8
variants visual
8
photodynamic therapy
8
polypoidal choroidal
8
choroidal vasculopathy
8
patients pcv
8
best-corrected visual
8
visual acuity
8
pdt responders
8

Similar Publications

The impact of visual fidelity on screen-based virtual reality food choices: A randomized pilot study.

PLoS One

January 2025

Department of Nutrition, College of Human Health and Development, The Pennsylvania State University, University Park, PA, United States of America.

Objective: To understand the impact of fidelity and perceived realism on virtual reality food choices, and task motivation, engagement, and interest.

Design: Randomized controlled trial.

Setting: Online.

View Article and Find Full Text PDF

Background: Ankle sprain is a common clinical disease, which has the highest incidence rate among joint and ligament injuries. And acute ankle sprains can easily develop into chronic ankle instability, thereby increasing the difficulty of treatment. The current clinical guidelines for post-acute ankle sprains are still controversial.

View Article and Find Full Text PDF

Ophthalmic Complications Associated With the Antidiabetic Drugs Semaglutide and Tirzepatide.

JAMA Ophthalmol

January 2025

John A. Moran Eye Center, Department of Ophthalmology & Visual Sciences, Department of Neurology, University of Utah Health, Salt Lake City.

Importance: Nearly 2% of the US population received a prescription for semaglutide in 2023. There has been a recent concern that this drug and other similar medications may be associated with ophthalmic complications.

Objective: To report ophthalmic complications associated with the use of semaglutide or tirzepatide.

View Article and Find Full Text PDF

Although microfocused ultrasound with visualization (MFU-V) and calcium hydroxylapatite- carboxymethylcellulose (CaHA-CMC) have their individual strengths and have demonstrated effectiveness in aesthetic improvement and improving skin laxity, a combined treatment may sometimes be required to achieve comprehensive aesthetic enhancements that meet patients' needs and preferences. This review systematically summarizes the available evidence on combined MFU-V and CaHA-CMC treatment. A comprehensive search was conducted in Embase, MEDLINE ALL (Ovid), Web of Science Core Collection, and Cochrane Central.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!